Fisetin

Best-in-class: Fisetin

A plant flavonoid and the leading candidate 'senolytic' — a compound that helps clear senescent 'zombie' cells that accumulate with age and drive inflammation.

How Fisetin actually works

Senescent cells are cells that have stopped dividing but refuse to die, and they secrete a persistent inflammatory cocktail — the senescence-associated secretory phenotype — that damages the tissue around them. They accumulate with age. A senolytic selectively pushes those cells into apoptosis, which they resist by upregulating specific survival pathways; fisetin appears to interfere with those. That's the basis for intermittent high-dose 'hit and run' protocols rather than daily use: you only need the drug present long enough to kill cells that are already flagged.

Where to get Fisetin

The evidence for Fisetin

Graded by what exists behind each claim.

✅ Clinically validated

• Human senolytic trials are ONGOING; current evidence is strong in animals (extended healthspan) and mechanistic in humans.
• Acts as an antioxidant and anti-inflammatory in human cell/tissue studies.

📊 Correlative data

• Senescent-cell burden rises with age and tracks with age-related disease.

🧪 Theoretical / extrapolated benefits

• The senolytic 'hit-and-run' longevity protocol (high-dose, 2–3 days/month) is popular and mechanistically exciting, but human outcome data isn't in yet.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Fisetin actually does

Fisetin is conjugated faster than it is absorbed, and that single fact is the gap between the mouse data and the bottle. It is a 3,3',4',7-tetrahydroxyflavone with a molecular weight of 286 daltons and 4 phenolic hydroxyl groups. Phenolic hydroxyls are the preferred substrate of UDP-glucuronosyltransferases and sulfotransferases, which are abundant in the enterocyte and the hepatocyte. An oral dose is therefore glucuronidated and sulfated during first pass, and free aglycone in plasma is a small and short-lived fraction of what was swallowed.

The senolytic mechanism is specific and it is about a survival program. A senescent cell is arrested but alive, and it stays alive by upregulating anti-apoptotic networks - BCL-2, BCL-XL and MCL-1 among them - that hold the mitochondrial apoptosis pathway in check. A senolytic knocks out that support and lets the cell finish dying. Fisetin was identified as the most effective senolytic among a panel of flavonoids in the work that also characterized BCL-XL inhibitors Zhu 2017, and that comparison is where the whole category came from.

Why removing those cells should matter is the senescence-associated secretory phenotype. A senescent cell secretes interleukin-6, interleukin-1 beta, tumor necrosis factor alpha and matrix metalloproteinases, and it recruits neighbors into senescence. Removing a small number of cells therefore has an effect out of proportion to their number, which is the premise of intermittent rather than continuous dosing.

The hit-and-run schedule follows from the biology and not from convenience. A senescent cell that has been killed does not come back, so the drug does not need to be present continuously; it needs to be present at a high enough concentration briefly. That is why the protocols are 2 to 3 consecutive days per month, and why intermittent supplementation is what the rodent arterial work used Mahoney 2023.

The pharmacokinetics are the reason this is difficult rather than impossible. Human pharmacokinetics have been measured, in a randomized double-blind crossover comparing a hybrid-hydrogel formulation against unformulated material in healthy individuals Krishnakumar 2022, and an entire review exists on the search for better fisetin bioavailability from macro to nano modifications Szymczak 2023. A compound with a dedicated bioavailability literature is a compound whose plain form does not deliver.

And there is a second, non-senolytic pharmacology that may be doing more of the work than anyone admits. Fisetin inhibits CD38, the principal NAD-consuming enzyme in mammalian tissue, and it activates Nrf2 and inhibits mTOR at concentrations achievable in cells. Those effects require sustained exposure rather than a monthly pulse, which means the 2 proposed mechanisms imply opposite dosing schedules.

Cell, rodent, human — and where it stops

This is a compound with excellent mouse data, real human pharmacokinetics and no human outcome trial, and the 3 should not be blurred together.

In cells. The senolytic screen that placed fisetin ahead of other flavonoids is the foundational result Zhu 2017. That is a cell-culture ranking at concentrations chosen by the experimenter.

In mice. Intermittent fisetin improved arterial function in old mice by decreasing cellular senescence, which is a mechanism-linked physiological endpoint rather than a marker Mahoney 2023. A separate study compared metabolic and cognitive responses to fisetin against a dasatinib and quercetin cocktail in mice and reported sex-dimorphic effects, which is a warning against assuming one answer fits everybody Fang 2023.

In people. The human dataset is pharmacokinetic. A randomized double-blind crossover measured plasma exposure from a formulated product against unformulated fisetin in healthy volunteers Krishnakumar 2022. No published randomized trial reports a clinical outcome.

Here is the obstacle, and it is arithmetic. Mouse senolytic protocols use doses around 100 mg per kilogram. Naive scaling to a 70 kg human gives 7 g per dose, and allometric scaling by body surface area still gives roughly 500 mg per kilogram equivalent in the region of hundreds of milligrams to grams. The commonly sold protocol of 1,000 to 1,500 mg for 2 to 3 days sits in that window on paper, and the pharmacokinetic problem means the plasma concentration reached is a different question from the milligrams taken Szymczak 2023.

The second obstacle is that senescent cell burden is not measurable in a living person. There is no validated blood test for it. Without a way to measure the target, a human trial has to use a downstream functional endpoint, which is slow and expensive, and that is why the trials are taking so long to appear.

Fisetin — which form, and does it matter

The form question is the only question, because plain fisetin powder delivers very little. A crystalline flavonoid with 4 phenolic hydroxyls and poor aqueous solubility, subject to extensive first-pass conjugation, is close to the worst-case oral compound. The review of formulation strategies from macro to nano modifications exists for precisely that reason Szymczak 2023.

Formulated products have measured human exposure and plain powder largely does not. A hybrid-hydrogel formulation was compared head-to-head against unformulated fisetin in a randomized crossover in healthy people Krishnakumar 2022. That is the kind of evidence a buyer should demand before paying a premium for any enhanced form, and most enhanced forms on sale do not have it.

Taking it with fat is the cheap version of a formulation. Fisetin is lipophilic and its absorption is improved by a fatty meal, which is why the card's instruction is to take it with fat. That is free, and it is doing the same job as a phospholipid complex less efficiently.

Purity is a real issue in this specific ingredient. Fisetin is extracted from smoke tree wood and from fruit sources, and commercial material is sold at 98 percent and at much lower assay values. Since the dose is already at the edge of what is achievable, a 50 percent extract at a 500 mg label is delivering half of a dose that was probably already too small Szymczak 2023.

And there is a form question in the schedule rather than the molecule. If the senolytic model is right, a monthly 2 to 3 day pulse is correct and daily dosing is wasteful Mahoney 2023. If the CD38 and Nrf2 mechanisms carry the effect, daily dosing is correct and the pulse is wasteful. Nobody has run the comparison, so the schedule on the label is a bet rather than a finding.

What would have to be true, and how you would know it was not

1. The prediction that the human data already support. On a formulated product, predict a measurably higher plasma fisetin concentration than on the same milligrams of plain powder, since that is what the crossover found Krishnakumar 2022. This is the one claim in the category with direct human evidence behind it.

2. The vascular prediction, which is the human version of the mouse result. Flow-mediated dilation or pulse wave velocity at baseline and after 6 monthly pulses. Prediction: an improvement in arterial function if the senolytic mechanism translates, since that is exactly the endpoint the mouse work moved Mahoney 2023. Nobody has published it in people, and it is the single most valuable measurement in this field.

3. The inflammatory prediction, at 3 and 6 months. hs-CRP and interleukin-6 measured before the first pulse and 4 weeks after the third and sixth. Prediction: if senescent cells are being cleared, the secretory phenotype markers fall between pulses rather than during them. A fall during a pulse is an acute anti-inflammatory effect, which is a different mechanism.

4. The prediction that cuts against the product. Predict that at 500 mg of unformulated powder taken with no fat, nothing measurable changes at all, because the plasma concentration never approaches the senolytic range Szymczak 2023. Most people taking this are running that experiment without knowing it.

5. The prediction that the mouse data specifically warn about. Sex-dimorphic responses were reported when fisetin was compared with a dasatinib and quercetin cocktail in mice Fang 2023. Predict that any human trial finds different effect sizes in men and women, and that a trial pooling them dilutes its own result.

What nobody has tested yet

Nobody has published a human outcome trial. The compound has cell data Zhu 2017, mouse physiology Mahoney 2023 and human pharmacokinetics Krishnakumar 2022. The trial with a clinical endpoint is missing and the category is being sold ahead of it.

Nobody can measure the target in a person. There is no validated circulating marker of senescent cell burden, which means neither a user nor a trialist can tell whether a dose did what it was supposed to do.

Nobody knows the right schedule. The senolytic model and the CD38 model imply opposite dosing patterns and no study has compared monthly pulses against daily dosing on any endpoint Mahoney 2023.

And nobody has established long-term safety. A compound that removes cells by disabling their survival program is not obviously benign over years, and no human study has run longer than a few weeks Szymczak 2023. That is an absence of data rather than an absence of risk.

Fisetin — its own safety story, not its category's

Short-term tolerability is good and long-term safety is unstudied, which is a different sentence from safe. The human pharmacokinetic work reports acceptable tolerability at the doses examined Krishnakumar 2022, and no human study has followed anybody for a year.

The interaction that matters most is anticoagulation. Flavonoids of this class affect platelet aggregation, and the high-dose pulse protocol concentrates any such effect into 2 or 3 days. Anyone on warfarin, a direct oral anticoagulant, aspirin or clopidogrel should treat a gram-dose pulse as a change worth telling a prescriber about.

Enzyme inhibition is the second interaction and it is under-characterized. Fisetin inhibits several cytochrome P450 isoforms and UDP-glucuronosyltransferases in vitro, which is expected for a polyphenol that is itself a conjugation substrate Szymczak 2023. Nobody has quantified this in people, so it is stated here as a direction with no magnitude.

The mechanism itself is the honest long-term concern. Apoptosis is how the body removes damaged cells, and a compound that modulates anti-apoptotic proteins is acting on a system with roles well beyond senescence Zhu 2017. There is no evidence of harm and there is also no long-term human data, and both halves belong in the same sentence.

Three groups where the answer is no. Pregnancy and breastfeeding, where a pro-apoptotic compound has no controlled exposure data; anyone in active cancer treatment, because interference with apoptotic signaling and with drug metabolism is exactly the wrong unknown to add; and anyone under 18. Nothing here is medical advice or a diagnosis, this is an experimental longevity compound rather than established medicine, and none of these statements has been evaluated by the Food and Drug Administration.

Sources read for this page

• Krishnakumar IM. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J Nutr Sci 2022 · PMID 36304817
• Szymczak J. Fisetin: In Search of Better Bioavailability - From Macro to Nano Modifications: A Review. Int J Mol Sci 2023 · PMID 37762460
• Mahoney SA. Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence. Aging Cell 2023 · PMID 38062873
• Zhu Y. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY) 2017 · PMID 28273655
• Fang Y, et al. Sexual dimorphic metabolic and cognitive responses of C57BL/6 mice to Fisetin or Dasatinib and quercetin cocktail oral treatment. GeroScience 2023 · PMID 37296266

How you would know if it worked

Fisetin — safety & side effects

Bloodwork to run alongside Fisetin

Baseline first, then again at 8–12 weeks.

The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.

Check results you already have → · All 103 markers A–Z

Fisetin — frequently asked questions

Fisetin inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Fisetin is used for

Fisetin appears under 1 goal in the goal router.

Related Longevity & Antioxidants supplements

← Browse the full Supplement Vault

↑ Back to on this page